A Case of Protracted Febrile Myalgia Syndrome with Atypical Course and Severe Asymmetric Loss of Muscle Strength.
P369S mutation
anakinra
familial Mediterranean fever
protracted febrile myalgia
Journal
Mediterranean journal of rheumatology
ISSN: 2529-198X
Titre abrégé: Mediterr J Rheumatol
Pays: Greece
ID NLM: 101730166
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
19
12
2022
revised:
18
01
2023
accepted:
01
02
2023
medline:
29
1
2024
pubmed:
29
1
2024
entrez:
29
1
2024
Statut:
epublish
Résumé
Protracted febrile myalgia syndrome (PFMS) is a rare form of familial Mediterranean fever (FMF) characterised by prolonged myalgia. The duration of PFMS is much longer than a typical 2-5-day attack familial Mediterranean fever and lasts for 2-6 weeks until they treated with corticosteroids. Colchicine is not effective for control of PFMS's attacks. The attacks typically resolve with corticosteroid and/or IL-1 receptor blockers. Herein, we present a young adult without typical familial Mediterranean fever clinical features but presenting with atypical course and severe asymmetric muscle strength loss. Thigh magnetic resonance imaging confirmed inflammation and oedema and muscle biopsy showed no pathological findings. Electromyography revealed myopathic findings during attack-period, despite normal results in attack-free study. The patient was treated successfully with anakinra and remarkable rapid recovery in both muscular findings and acute phase reactants were observed. PFMS should be considered even in the absence of apparent FMF attack pattern and in the presence of unexpected severe muscle weakness, especially in areas endemic for FMF and long-lasting myalgia attacks.
Identifiants
pubmed: 38282944
doi: 10.31138/mjr.300723.aco
pii: MJR-34-4-550
pmc: PMC10815528
doi:
Types de publication
Case Reports
Langues
eng
Pagination
550-554Informations de copyright
© 2023 The Mediterranean Journal of Rheumatology (MJR).
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.